Navigation Links
The H1N1 flu vaccine protects both pregnant women and newly-borns

The researchers studied the immune response of 107 pregnant women after they were injected with a single dose of non-adjuvant H1N1 vaccine. They concluded that the influenza shot boosted the immune response in pregnant women and at the same time protected neuronatal babies via the antibodies that transferred through the placenta.

These results were published in the review Annals of Internal Medicine dated December 6th,.2011. They are available on-line at:

Influenza (the flu) is a contagious, acute respiratory infection caused by the family of viruses Influenzae. There are three types of Influenza virus: A, B and C. The A and B viruses cause seasonal (or winter) epidemics, but only the A virus is responsible for worldwide epidemics. Very soon into the worldwide influenza epidemic of 2009, pregnant women and neonatal babies were found to be at very high risk of complications and death if infected, as had already been observed during previous worldwide influenza epidemics. As early as August 2009, a study published in The Lancet showed that 10% of the serious cases were observed in pregnant women, whereas they represented only 1% of the total French population. So H1N1 influenza vaccination of pregnant women was recommended as a priority.

The team led by Odile Launey, the Director of vaccinology at the Centre for Clinical Investigation at Cochin Pasteur (Inserm/AP-HP/Institut Pasteur/Universit Paris Descartes), carried out a vaccination study in order to demonstrate the immunogenicity, in other words the immune response in terms of the production of antibodies, after a single injection of a nonadjuvant A strain (H1N1) into women at 21 days and 42 days of gestation and to measure the transplacentary transfer of the mother's antibodies to neonatal babies.

This study concerned 107 women between 22 and 32 weeks of amenorrhea who were monitored in 5 French neonatal clinics between November 3rd and December 4th 2009 after being injected into the arm with an injection of H1N1 A strain vaccine.

Blood tests were carried out in order to measure the antibody counts protecting against the influenza virus:

  • Piror to vaccination
  • 3 and 6 weeks after vaccination
  • At delivery
  • 3 months after delivery

On delivery, a blood sample is taken from the umbilical cord in order to measure the quantity of influenza antibodies transmitted to the newly born. All events observed in mothers and babies during the study were recorded.

Prior to vaccination, 19% of the patients already presented H1N1 strain antibodies at levels considered to be protective. Three and six weeks after vaccination, 98% of the patients presented blood antibody counts considered to be protective. On delivery and 3 weeks after delivery, the proportion of patients with antibody counts considered to be protective were between 92% and 90%. The umbilical cord samples of newly born babies showed antibody counts considered to be protective in 95% of cases, some antibody concentrations were even higher than in the mothers (a ratio of 1.4 between neonatal babies concentrations and maternal concentrations at delivery).

"These results show that the influenza vaccine boosts the immune system in pregnant women and also protects newly-borns via transplacenta transfer ", concludes Odile Launay.

This study and an increasing number of other studies on pregnant women have confirmed the non-toxicity of the influenza vaccine during pregnancy. This year again, pregnant women are strongly recommended to take the influenza vaccine. The composition of the vaccine is modified each year to cover the major strains of the previous winter, which are the strains most likely to be present the next winter. "The H1N1 2009 virus is still around. That's why the inactivated H1N1 virus is still present in the current seasonal influenza vaccine". So it is highly recommended to vaccinate pregnant women in order to protect them and their baby, because otherwise the vaccine cannot be administered to babies before the age of 6 months", explains Odile Launay.

Contact: Inserm Presse
INSERM (Institut national de la sant et de la recherche mdicale)

Related biology news :

1. Childrens National researchers develop novel anti-tumor vaccine
2. RNA molecules, delivery system improve vaccine responses, effectiveness
3. Bird flu vaccine protects people and pets
4. Research identifies type of vaccine that holds promise in protecting against TB
5. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
6. Flu shot protects kids -- even during years with a bad vaccine match
7. New type of vaccines deliver stronger and faster immune response
8. Fractional dose of scarce meningitis vaccine may be effective in outbreak control
9. Vaccines and autism: Many hypotheses, but no correlation
10. New vaccine developed for preventing uncommon cold virus
11. African-Americans aware and accepting, but often do not receive, the HPV vaccine
Post Your Comments:
(Date:11/9/2015)... 2015 ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... 2015 Daon, a global leader in mobile ... a new version of its IdentityX Platform , ... America have already installed IdentityX v4.0 and ... FIDO UAF certified server component as an ... FIDO features. These customers include some of the largest ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... in New York on Wednesday, December 2 ... Torley , president and CEO, will provide a corporate overview. ... York at 1:00 p.m. ET/10:00 a.m. PT . ... relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... -- Clintrax Global, Inc., a worldwide provider of clinical research services headquartered ... the company has set a new quarterly earnings record in Q3 ... posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , with ...
(Date:11/24/2015)... 2015 --> ... released by Transparency Market Research, the global non-invasive prenatal ... of 17.5% during the period between 2014 and 2022. ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ... market to reach a valuation of US$2.38 bn by ...
Breaking Biology Technology: